Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Surg Oncol. 2020 Feb 8;33:118–125. doi: 10.1016/j.suronc.2020.02.003

Table 3.

A summary of each patient’s sex, pathologic diagnosis, all relevant sequence coding region sequence changes, and proteomic findings.

SEX DIAGNOSIS GENOMIC FINDINGS
Male Pancreatic adenocarcinoma HER2 S310F, KRAS G12D, p53 R282W, CSF1R T37M, GATA6 Amplification, RBM10 Y508*
Male Pancreatic adenocarcinoma HER2 Amplification, KRAS G12R, p53 H193P, MYC Amplification
Male Pancreatic adenocarcinoma CHEK2 T367fs*15, KRAS G12D, NF1 Truncation exon 35, DNMT3A C818*
Female Pancreatic adenocarcinoma KRAS G12V, p53 R248W, CDKN2A Loss, SMAD4 V112fs*8
Female Pancreatic adenocarcinoma KRAS G12D, p53 Y220C, CDKN2A R80*, SMAD4 R361C
Female Pancreatic adenocarcinoma BRCA2 T3085fs*19
Male Pancreatic adenocarcinoma KRAS G12V, p53 P153fs*28, CDKN2A Loss, CCNE1 Amplification, SOX2 Amplification, MAP2K2 Amplification, PIK3CA Amplification, PRKCI Amplification, SNCAIP R499W, TERC Amplification
Male Pancreatic adenocarcinoma KRAS G12D, p53 I195F, CDKN2A Loss, CCND1 Amplification, EMSY Amplification, GATA6 Amplification, FGF19 Amplification, FGF3 Amplification, FGF4 Amplification, LRP1B deletion exon 4–16
Male Pancreatic adenocarcinoma ATM K2589fs*8, KRAS Q61R, p53 L43fs*9, CDKN2A Loss, SMAD4 V163fs*3, GATA6 Amplification, MAGI2 M593V, SLIT2 A276T
Male Pancreatic adenocarcinoma KRAS G12D, p53 Y163C, PRKN Rearrangement
Male Pancreatic adenocarcinoma BRCA2 C1200fs*1, HER2 H878Y, KRAS G12R, SMAD4 D493H, SMAD4 V335fs*48, BRCA2 R2336H
Male Pancreatic adenocarcinoma KRAS G12D, p53 K319_K320insKKPLDGEYFT*, AKT2 Amplification, CCNE1 Amplification
Male Pancreatic adenocarcinoma KRAS G12D, p53 M237_N239del2
Male Pancreatic adenocarcinoma KRAS G12D, p53 C176Y, CDKN2A R80*, CDKN2A Truncation, intron 1, AKT2 Amplification, MYC Amplification
Male Pancreatic adenocarcinoma KRAS G12V, p53 A159fs*21, ARID1A Q575*, ARID1A S1828*, SLIT2 N775S
Female Pancreatic adenocarcinoma FGFR1 Amplification, KRAS G12V, p53 H214R, CDKN2A Loss
Male Pancreatic adenocarcinoma KRAS G12V, p53 G266E
Male Pancreatic adenocarcinoma KRAS G12D, p53 P278L, CDKN2A R22_G23del
Female Pancreatic adenocarcinoma KRAS G12V
Female Pancreatic adenocarcinoma PALB2 P1152fs*9, FGFR2 P253R, PALB2 S804fs*10, PRKCI Amplification, SLIT2 A276T, TERC Amplification
Male Pancreatic adenocarcinoma KRAS Q61H, ARID1A R1335*2
Female Pancreatic adenocarcinoma ATM K1066fs*6, KRAS G12D, MDM2 Amplification, ARID1A Y216*, FRS2 Amplification, ATM W1710*, KMT2D P601fs*329
Female Pancreatic adenocarcinoma KRAS G12D, p53 G266E
Male Pancreatic adenocarcinoma KRAS G12D, p53 M133K, CDKN2A H83D, SMAD4 Loss, MUTYH Y165C
Female Pancreatic adenocarcinoma BRCA1 Rearrangement intron 2, KRAS G12V, p53 R249S, CDKN2A Loss, MYC Amplification, PIK3CA Amplification, PRKCI Amplification, TERC Amplification
Male Pancreatic adenocarcinoma KRAS G12D
Female Pancreatic adenocarcinoma KRAS G12D, p53 C124*, CDKN2A Loss
Female Pancreatic adenocarcinoma KRAS G12V, p53 R213*, CDKN2A Loss, RICTOR Amplification, STAG2 X435_splice
Male Pancreatic adenocarcinoma KRAS G12D, p53 R175H, GNAS R201H, RNF43 E43*
Female Pancreatic adenocarcinoma KRAS G12D, p53 C176F, CDKN2A Loss, RNF43 E777fs*10+, GATA6 Amplification
Female Pancreatic adenocarcinoma BARD1 S551*, KRAS G12R, p53 Q136*, p53 S366A, CDK12 Truncation, CDK12 Truncation exon 10, MYC Amplification, DNMT3A R729W, GRM3 D280N, MYC Amplification equivocal, RUNX1T1 R520H
Male Pancreatic adenocarcinoma ABL2 Rearrangement, KRAS Q61H
Female Pancreatic adenocarcinoma KRAS G12R, p53 W91*, SMAD4 R445*
Female Pancreatic adenocarcinoma KRAS G12V, p53 V157F, CDKN2A Loss
Female Pancreatic adenocarcinoma KRAS G12V, p53 A76fs*55, SMARCA4 T910M
Female Pancreatic adenocarcinoma BRCA2 L557*, KRAS G12V, p53 R248W, CDKN2A X51_splice, CDKN2A X0_splice, DNMT3A R882H, FAT1 Y4540fs*8, HGF Amplification, EPHB1 R79W, HGF Amplification equivocal
Male Pancreatic adenocarcinoma KRAS Q61H, p53 R213*, CDKN2A A17fs*9
Female Pancreatic adenocarcinoma KRAS G12V, p53 R248Q
Male Pancreatic adenocarcinoma KRAS G12D, CDKN2A H83R
Female Pancreatic adenocarcinoma KRAS G12V, p53 G334V, BRSK1 Loss exon 2–17
Male Pancreatic adenocarcinoma KRAS Q61H, p53 Q192*, CDKN2A R87fs*21, SMAD4 W302*, KDM6A E226*, PBRM1 R710*, HGF E199K, LRP1B D2702N
Female Pancreatic adenocarcinoma KRAS G12R, p53 X307_splice, SMAD4 R361H, SMAD4 R445*, CCND3 Amplification, VEGFA Amplification, APC I2615fs*1, TMB Intermediate
Male Pancreatic adenocarcinoma KRAS G12V, p53 V157F, NOTCH2 Amplification
Male Pancreatic adenocarcinoma KRAS Q61R, p53 R337C, SMAD4 G286fs*50, MYCL Amplification, CCNE1 Amplification, MYCL Amplification equivocal
Female Pancreatic adenocarcinoma KRAS G12D, p53 R213W, CDKN2A H83Y, SMAD4 C523*, ARID1A D322fs*40, TMB Intermediate
Male Pancreatic adenocarcinoma KRAS G12R, p53 Y220C, CDKN2A Loss, TGFBR2 R537C
Male Pancreatic adenocarcinoma KRAS G12D, p53 R282W, CDKN2A Loss, SMAD4 Truncation intron 4, SMAD4 Truncation, NOTCH3 deletion exon 7–31, NOTCH3 deletion
Female Pancreatic adenocarcinoma KRAS G12V, p53 D49fs*76, RBM10 L195fs*71
Female Pancreatic adenocarcinoma KRAS G12D
Female Pancreatic adenocarcinoma KRAS G12D, p53 R175H, NTRK3 K732T
Male Pancreatic adenocarcinoma KRAS G12V, p53 R196*, CDKN2A L94P
Female Pancreatic adenocarcinoma KRAS G12D, p53 R282W
Female Pancreatic adenocarcinoma KRAS G12D, SMAD4 S474*
Male Pancreatic adenocarcinoma p53 R282W
Male Pancreatic adenocarcinoma KRAS G12C, p53 G245D, MYCL R330*, VEGFA Amplification, SF3B1 K666R, VEGFA Amplification equivocal
Male Pancreatic adenocarcinoma KRAS G12D, p53 V218E, CDKN2A A100fs*46, NF1 X244_splice
Female Pancreatic adenocarcinoma KRAS G12D, p53 D281fs*31, KDM6A A516fs*9, SETD2 X2037_splice, DNMT3A K844*, TMB Intermediate, SPTA1 T681fs*76
Male Pancreatic adenocarcinoma KRAS G12D, p53 C141fs*8
Female Pancreatic adenocarcinoma KRAS G12D, p53 P322fs*23, ARID2 Loss, ARID2 Loss exon 17–21
Male Pancreatic adenocarcinoma FANCG W599fs*49, KRAS G12V
Female Pancreatic adenocarcinoma KRAS G12D, DNMT3A R771*
Female Pancreatic adenocarcinoma KRAS G12V, p53 H193R, SMAD4 W99*, CUL3 R709Q
Female Pancreatic adenocarcinoma KRAS G12V, p53 V173L, CDKN2A deletion exon 2, CDKN2A deletion exon 2 - intron 2, SMAD4 Q116*, FRS2 Amplification
Female Pancreatic adenocarcinoma ATM Q1084fs*9, KRAS G12V, CDKN2A M54del, SMAD4 Q28*
Male Pancreatic adenocarcinoma KRAS G12V, SMAD4 Truncation intron 8
Female Pancreas neuroendocrine carcinoma MEN1 L89R
Female Extrahepatic cholangiocarcinoma STK11 R304W, MDM2 Amplification, FRS2 Amplification, U2AF1 S34F
Male Extrahepatic cholangiocarcinoma p53 W91*, CDKN2A R107fs*37, AKT1 Amplification, NCOR2 G781fs*15
Male Extrahepatic cholangiocarcinoma KRAS Amplification, KRAS G12V, p53 G293fs*13, SF3B1 K700E
Female Extrahepatic cholangiocarcinoma SPEN M2790V, KRAS G12V, CTNNB1 S45F, CD36 C243*
Male Duodenal adenocarcinoma KRAS G12D, p53 R213*, ERBB3 G284R
Male Colon adenocarcinoma KRAS G12V, GNAS R201H
Male Ampullary adenocarcinoma KRAS G12D, APC K1543fs*2, FH V435M, MAP2K4 S251N
Male Ampullary adenocarcinoma BARD1 Y404fs*1, CIC G797fs*114
Male Ampullary adenocarcinoma BRCA2 E1518fs*25
Female Ampullary adenocarcinoma HER2 D769Y, p53 G245V
Female Solid pseudopapillary neoplasm of the pancreas CTNNB1 S37A
Female Solid pseudopapillary neoplasm of the pancreas CTNNB1 I35_G38del

TMB was either low or not reported unless otherwise specified; Microsatellite instability was not detected in any of these cases.